Heparin Sodium 5,000 Units IN Dextrose 5%



Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 42.6%
Drug Use For Unknown Indication 40.7%
Deep Vein Thrombosis 3.2%
Pulmonary Embolism 1.9%
Thrombosis Prophylaxis 1.4%
Myocardial Infarction 1.3%
Cerebrovascular Accident 1.2%
Anticoagulant Therapy 1.1%
Pain 1.1%
Atrial Fibrillation 0.8%
Prophylaxis 0.8%
Coronary Artery Bypass 0.5%
Diabetes Mellitus 0.5%
Chest Pain 0.4%
Chronic Obstructive Pulmonary Disease 0.4%
Coagulopathy 0.4%
Haemodialysis 0.4%
Mineral Supplementation 0.4%
Acute Myocardial Infarction 0.3%
Aortic Valve Replacement 0.3%
Vomiting 12.9%
Unresponsive To Stimuli 10.8%
Activated Partial Thromboplastin Time Prolonged 7.5%
Drug Ineffective 7.5%
Incorrect Drug Administration Rate 6.5%
Blood Pressure Decreased 5.4%
Haemorrhagic Stroke 5.4%
Pulmonary Embolism 5.4%
Dizziness 4.3%
Drug Level Below Therapeutic 4.3%
Death 3.2%
Heparin-induced Thrombocytopenia 3.2%
Medication Error 3.2%
Neck Pain 3.2%
Overdose 3.2%
Rash 3.2%
Rash Pruritic 3.2%
Renal Failure 3.2%
Activated Partial Thromboplastin Time Shortened 2.2%
Asthenia 2.2%
Secondary
Product Used For Unknown Indication 62.9%
Drug Use For Unknown Indication 21.5%
Thrombosis Prophylaxis 1.6%
Mesenteric Vein Thrombosis 1.4%
Splenic Vein Thrombosis 1.4%
Catheterisation Cardiac 1.3%
Pulmonary Embolism 1.1%
Intravenous Catheter Management 1.1%
Deep Vein Thrombosis 0.9%
Coronary Artery Bypass 0.8%
Central Venous Catheterisation 0.8%
Pain 0.8%
Prophylaxis 0.8%
Atrial Fibrillation 0.7%
Arteriogram Coronary 0.6%
Anticoagulant Therapy 0.5%
Haemodialysis 0.5%
Continuous Haemodiafiltration 0.5%
Respiratory Disorder 0.4%
Surgery 0.4%
Vomiting 20.1%
Swelling 13.5%
Unresponsive To Stimuli 9.9%
Tachycardia 6.6%
White Blood Cell Count Increased 4.9%
Ventricular Tachycardia 4.8%
Erythema 4.6%
Abdominal Compartment Syndrome 4.1%
Cardiac Disorder 4.1%
Organ Failure 4.1%
Thrombocytopenia 3.9%
Vision Blurred 2.8%
Upper Gastrointestinal Haemorrhage 2.5%
Hypotension 2.4%
Urinary Tract Infection 2.1%
Vena Cava Thrombosis 2.1%
Pyrexia 2.0%
Activated Partial Thromboplastin Time Prolonged 1.9%
Haemodynamic Instability 1.9%
Thrombosis 1.9%